Predicting Response to Chemotherapy in Colorectal Cancer Via Multi-dimensional Analyses of the Tumor Associated Neutrophils

Fudan University

Status

Completed

Conditions

Tumor Associated Neutrophils

Treatments

Other: No different intenvention

Study type

Observational

Funder types

Other

Identifiers

NCT06495827

TANs for CT response in CRC

Details and patient eligibility

About

A single biomarker is not adequate to identify patients with colorectal cancer (CRC) who have the potential to benefit from adjuvant therapy, presumably owing to the complexity of tumor-infiltrating immune cells (TIICs). The density and spatial organization of TIICs has not been definitely established to explore their predictive value. This study aimed to investigate the prognostic significance of TIICs and its biological predictive value in CRC.

Enrollment

653 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Voluntarily sign a written ICF.
The Eastern Cancer Collaborative Organization (ECOG) has a physical fitness score of 0 or 1.
The expected survival period is ≥ 3 months.
Subjects diagnosed with metastatic colorectal adenocarcinoma by histology or cytology.
Colorectal cancer patients who have not received systematic anti-tumor therapy in the past.

Exclusion criteria

Subjects suffered from other malignant tumors within 3 years before enrollment, except for cured local tumors (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, etc.).
Simultaneously enroll in another clinical study, unless it is an observational, non-interference clinical study or a follow-up period of an intervention study.
Received systematic anti-tumor therapy (chemotherapy) within 3 weeks prior to the first administration